Logo image of KALA

KALA BIO INC (KALA) Stock Price, Quote, News and Overview

NASDAQ:KALA - Nasdaq - US4831192020 - Common Stock - Currency: USD

6.64  -0.2 (-2.92%)

KALA Quote, Performance and Key Statistics

KALA BIO INC

NASDAQ:KALA (2/21/2025, 8:00:02 PM)

6.64

-0.2 (-2.92%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High11.2
52 Week Low4.21
Market Cap40.44M
Shares6.09M
Float5.65M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)03-27 2025-03-27/amc
IPO07-20 2017-07-20


KALA short term performance overview.The bars show the price performance of KALA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 -20 -30

KALA long term performance overview.The bars show the price performance of KALA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of KALA is 6.64 USD. In the past month the price decreased by -18.53%. In the past year, price decreased by -5.95%.

KALA BIO INC / KALA Daily stock chart

KALA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About KALA

Company Profile

KALA logo image KALA BIO, Inc. is a biopharmaceutical company. The company is headquartered in Arlington, Massachusetts and currently employs 43 full-time employees. The company went IPO on 2017-07-20. The firm is engaged in the research, development and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived bio factors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its KPI-012 is used for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The firm is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.

Company Info

KALA BIO INC

1167 Massachusetts Avenue

Arlington MASSACHUSETTS 02472 US

CEO: Mark Iwicki

Employees: 43

Company Website: https://www.kalarx.com/

Investor Relations: https://investors.kalarx.com/

Phone: 17819965252

KALA BIO INC / KALA FAQ

What is the stock price of KALA BIO INC today?

The current stock price of KALA is 6.64 USD. The price decreased by -2.92% in the last trading session.


What is the ticker symbol for KALA BIO INC stock?

The exchange symbol of KALA BIO INC is KALA and it is listed on the Nasdaq exchange.


On which exchange is KALA stock listed?

KALA stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for KALA BIO INC stock?

8 analysts have analysed KALA and the average price target is 15.3 USD. This implies a price increase of 130.42% is expected in the next year compared to the current price of 6.64. Check the KALA BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is KALA BIO INC worth?

KALA BIO INC (KALA) has a market capitalization of 40.44M USD. This makes KALA a Nano Cap stock.


How many employees does KALA BIO INC have?

KALA BIO INC (KALA) currently has 43 employees.


What are the support and resistance levels for KALA BIO INC (KALA) stock?

KALA BIO INC (KALA) has a support level at 6.39 and a resistance level at 6.64. Check the full technical report for a detailed analysis of KALA support and resistance levels.


Should I buy KALA BIO INC (KALA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does KALA BIO INC (KALA) stock pay dividends?

KALA does not pay a dividend.


When does KALA BIO INC (KALA) report earnings?

KALA BIO INC (KALA) will report earnings on 2025-03-27, after the market close.


What is the Price/Earnings (PE) ratio of KALA BIO INC (KALA)?

KALA BIO INC (KALA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-12.46).


What is the Short Interest ratio of KALA BIO INC (KALA) stock?

The outstanding short interest for KALA BIO INC (KALA) is 2.82% of its float. Check the ownership tab for more information on the KALA short interest.


KALA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

KALA Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to KALA. KALA may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

KALA Financial Highlights

Over the last trailing twelve months KALA reported a non-GAAP Earnings per Share(EPS) of -12.46. The EPS increased by 45.18% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -62.84%
ROE -282.23%
Debt/Equity 1.66
Chartmill High Growth Momentum
EPS Q2Q%43.4%
Sales Q2Q%N/A
EPS 1Y (TTM)45.18%
Revenue 1Y (TTM)-100%

KALA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to KALA. The Buy consensus is the average rating of analysts ratings from 8 analysts.


Ownership
Inst Owners57.11%
Ins Owners2.35%
Short Float %2.82%
Short Ratio2.45
Analysts
Analysts85
Price Target15.3 (130.42%)
EPS Next Y38.4%
Revenue Next YearN/A